Phase
Condition
N/ATreatment
N/AClinical Study ID
Ages 18-90 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Patients with osteoarthritis of the hip secondary to degeneration, inflammatoryarthritis, gouty arthritis, acetabular dysplasia or osteonecrosis of the femoral head,and undergoing primary unilateral minimally invasive THA
Age > 18 years and < 90 years
Failure of medical treatment or rehabilitation.
Hemoglobin > 11g/dl,
No use of non-steroid anti-inflammatory agent one week before operation
Exclusion
Exclusion Criteria:
Preoperative Hemoglobin ≦11 g/dl
History of infection or intraarticular fracture of the affective hip
Renal function deficiency (GFR <30 ml/min/1.73m2)
Elevated liver enzyme (aspartate transaminase (AST)/ alanine transaminase(ALT) levelare more than twice normal range) , history of liver cirrhosis, impaired liverfunction(elevated total bilirubin level) and coagulopathy (including long-term useanticoagulant)
History of deep vein thrombosis, ischemic heart disease or stroke
Contraindications of tranexamic acid, floseal, or rivaroxaban
Allergy to tranexamic acid, floseal, rivaroxaban, or the excipients
History of heparin-induced thrombocytopenia (HIT)
Coagulopathy or bleeding tendency caused by organ dysfunction, such as cirrhosis, bonemarrow suppression etc.
Patient who have active bleeding disorder, such as intracranial hemorrhage, uppergastrointestinal bleeding, hematuria.
Patients with known allergies to materials of bovine origin.
Study Design
Connect with a study center
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung,
TaiwanActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.